Articles tagged with Drug Therapy
Researchers at Berkeley Lab have made significant breakthroughs in developing a highly effective COVID-19 antibody therapy and an efficient thermoelectric system that can convert waste heat to electricity. The new antibody, S309, has been shown to neutralize all known SARS-CoV-2 strains and may be more difficult for new mutants to escape.
Researchers found that some medications used to treat autoimmune rheumatic diseases can weaken the immune response to COVID-19 vaccines. Vaccination still induced an immune response in patients, but at a lower rate than in those without autoimmune diseases.
Researchers found individuals with well-controlled asthma have significantly lower odds of hospitalization and ICU admission compared to those with uncontrolled asthma. Asthma patients using their medications showed a decrease in worsened COVID-19 outcomes.
Computational modeling reveals that smaller drug particles can reach the distal region of airways, improving treatment efficacy. The study aims to enhance inhaler design and reduce drug loss, benefiting patients with respiratory illnesses.
Researchers have modelled how drugs are delivered to the respiratory tract via an inhaler to better treat lung diseases. Finer drug particles of around one micron are better able to travel further into the lungs.
The article considers the ethical issues surrounding enrolling children with neurodevelopmental conditions, such as autism spectrum disorder and fragile X syndrome, in clinical trials. Parents may face difficult decisions about whether to enroll their children due to concerns about potential loss of positive aspects of their condition.
Despite guidelines and legal requirements, women remain underrepresented in cardiovascular clinical trials, limiting treatment data on cardiovascular disease. Research shows that women respond differently to drugs than men, highlighting the need for sex-specific data in optimal care.
A four-year cohort study identified a significant link between midazolam exposure and elevated posttraumatic stress symptoms in children. Symptoms were found to be persistent for up to 12 months, highlighting the need for early intervention and psychosocial support.
A new study developed a wearable technology-based method to assess myoclonus symptoms in the home environment. The method, which measures electrical neuromuscular function and movement, correlates well with assessments performed by experienced physicians.
Researchers at St. Jude Children's Research Hospital have developed a more accurate laboratory model for studying retinoblastoma, a rare pediatric eye cancer. The models closely mimic the biology of patient tumors and provide an important resource for studying the earliest stages of the disease as well as screening new therapies.
A new process for making RNA has been developed by researchers at the University of Massachusetts Amherst, yielding purer and more abundant RNA at a fraction of the cost. This breakthrough removes the largest stumbling block on the path to next-generation RNA therapeutic drugs.
A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.
A big data study from UNSW Sydney found that Australian cancer patients kept up their pharmaceutical treatments during last year's COVID-19 lockdowns. The researchers attribute the good news to relatively low rates of COVID-19 infections in Australia, which minimally impacted cancer treatment patterns.
Researchers analyzed patient specimens and clinical trial data from thousands of patients to assess the importance of immune cell molecules called Fc gamma receptors (FCGRs) in the therapeutic efficacy of two antibody drugs. High levels of FCGR2B on tumor cells were found to prevent rituximab efficacy, while obinutuzumab was not impact...
Researchers at University of California San Diego School of Medicine modified remdesivir to create an oral version that can be taken earlier in COVID-19 diagnoses. The revised drug proved effective and safe in cell and animal studies.
Researchers at Boston Children's Hospital report positive results with risplidam, a small-molecule drug that treats SMA by correcting the root cause: a mutated gene. Infants receiving risplidam showed improvements in motor function and lived longer than expected.
Researchers discovered how protective molecules like SPM are altered in COVID-19 patients, suggesting that increasing these molecules could limit inflammation and disease severity. The study also found that dexamethasone increased SPM production, improving white blood cell function and reducing inflammation.
A phase 2 clinical trial found that ibrutinib is a safe and effective treatment option for patients with relapsed or variant forms of hairy cell leukemia. The study, conducted at Ohio State University Wexner Medical Center, showed improved cancer control for this high-risk patient group.
A new way to target the RAS protein, responsible for 20-30% of all known cancers, has been found by a team from the University of Leeds. This breakthrough could lead to greater treatments for more patients, paving the way for hundreds of other disease targets.
A new analysis by Temple University researchers found that endovascular stenting is highly effective in treating superior vena cava syndrome, with a success rate of nearly 99%. The therapy has also shown low restenosis and recurrence rates, making it the preferred option for patients with this condition.
A large study of over 1.8 million women has found no link between fertility drugs and an increased risk of breast cancer. The research, published in Fertility and Sterility journal, provides reassurance to women seeking fertility treatments.
The company's 3D Predict assay has been validated for predicting responses to temozolomide in glioblastoma patients, with predictive accuracy comparable to its previous results in ovarian cancer. The test identifies future responders and non-responders, enabling personalized treatment strategies.
A study of 614 children found that corticosteroids reduced inflammation levels by half within a day, with similar recovery rates to immunoglobulin treatments. Corticosteroids may be a cheaper alternative to immunoglobulin, which is in short supply and expensive.
A new radiopharmaceutical, 18F-DASA-23, has successfully visualized the 'master switch' protein PKM2 in glioblastoma patients. This allows for non-invasive assessment of treatment response and potential early detection of therapeutic effectiveness.
Dr. Larson has been named recipient of the prestigious Paul C. Aebersold Award for his contributions to cancer imaging and radionuclide therapy. He is a world-renowned expert in radiopharmaceutical therapy and molecular imaging.
Research suggests that Nintendo Wii therapy can significantly improve balance in children with cerebral palsy, even when combined with conventional physical therapy. The analysis found medium to large effects of the therapy on functional balance and dynamic balance, respectively.
A new study analyzing medical evidence on domestic mass shooters in the US finds that a majority of perpetrators have psychiatric disorders without treatment, increasing risk of violence. The researchers identified signs and symptoms of brain illness in 32 out of 35 perpetrators, with most having schizophrenia or other diagnoses.
Researchers have developed a new categorization system for vasculitis based on its underlying immunological causes, which may lead to more effective treatments and better patient outcomes. The study identified key differences in disease response to various treatments, paving the way for new clinical trials.
A new type of penile traction therapy (PTT) device has been shown to increase penile length and preserve erectile function in men who have undergone prostate cancer surgery. The device, marketed under the brand name RestoreX, works by applying gentle, dynamic pressure to stretch and shape the penis.
Scientists have created a miniature 3D bone marrow model that can predict patient responses to Eltrombopag therapy for platelet disorders. The model uses silk protein scaffolding and patient-derived cells to recreate human bone marrow conditions.
Researchers found that selective serotonin reuptake inhibitors can reduce deterioration of intellectual abilities in individuals with a microdeletion of chromosome 22. The study suggests a potential neuroprotective effect and opens up new research possibilities.
The American Gastroenterological Association (AGA) recommends early introduction of biologics for patients with moderate-to-severe luminal and fistulizing Crohn's disease. Biologics are the most effective treatment option, which should be used early rather than delaying their use until other treatments fail.
A breakthrough study by Anglia Ruskin University experts suggests that cataract treatment could shift from surgery to drug therapy, offering exciting implications for public health. The research found the role of aquaporin proteins in lens development and highlights the potential for nanotechnologies to support drug-based therapies.
A Phase 1 study of Z-endoxifen in patients with solid tumors reported partial responses in three patients and prolonged stable disease in eight. The study suggests that Z-endoxifen can benefit patients who have progressed on tamoxifen treatment, particularly those with desmoid tumors.
A recent study found that only 6% of people with alcohol use disorder receive treatment, despite most having access to healthcare. The researchers suggest that primary care doctors may not feel comfortable addressing drinking issues due to lack of training, leading to a gap in treatment.
A team of researchers has developed first-in-class small molecules to inhibit the SET domain of the ASH1L protein, preventing critical molecular interactions in leukemia development. The lead compound, AS-99, successfully reduced leukemia progression in mouse models.
Researchers have developed a novel nano-carrier to deliver the Chinese medicine compound gambogic acid, enhancing its anti-cancer effect and reducing off-target toxicity. The treatment shows promise in treating triple-negative breast cancer with improved efficacy and reduced damage to organs.
A network meta-analysis of 58 randomized controlled trials involving 9,301 patients found that psychotherapy and pharmacotherapy were significantly more effective than care-as-usual or waitlist control. Combined treatment, particularly cognitive behavioral therapy, was better than either treatment alone.
Researchers analyzed records from two large U.S. databases to examine the relationship between erythropoietin doses and hip fracture rates in patients with kidney failure. They found that fluctuations in EPO doses over time closely tracked average EPO dose used, highlighting a potential increased risk of hip fractures.
The Digital Display Precision Predictor (DDPP) is a global biomarker model that predicts the duration of progression-free survival for cancer patients undergoing targeted therapy. It provides insight into the status of activation of almost all drug targets in tumor progression, enabling optimal treatment selection.
A Monash University study has discovered a way to prevent and reverse the damage caused by broken-heart syndrome, also known as Takotsubo cardiomyopathy. The breakthrough uses Suberanilohydroxamic acid to target genes and improve cardiac health.
Researchers at Einstein College of Medicine developed a topical drug that regenerates and restores function of erectile nerves damaged by radical prostatectomy. The siRNA gel enhanced nerve regeneration and restored nerve function in rat models, restoring erectile function.
Researchers at the University of Cincinnati have developed a new treatment for Pompe disease, a genetic condition that affects 1 in 40,000 people in the US. The treatment has been shown to be safer and more effective than current therapy, improving respiratory muscle function, endurance, and overall quality of life.
Researchers found that about 25% of study participants developed vision loss from glaucoma, a lower rate than expected. The conventional thinking was that most patients with elevated eye pressure should receive treatment due to high costs and potential side effects.
A team led by Dr. Bradley Peterson plans a foundational study into treating childhood anxiety, comparing cognitive behavioral therapy (CBT) and medication. The multi-center study will recruit 404 youth and assess treatment strategies to provide evidence-based guidance for medical professionals and families.
A new study by UC researchers uses brain imaging to predict treatment outcomes for adolescents with anxiety disorders. The study showed that medication can 'dampen' the overactivity of fear areas in the brain, leading to improved transmission of messages between neurons.
The UPMC/Pitt team established a largest and most equitable distribution network for COVID-19 monoclonal antibody infusions across Pennsylvania. The treatment reduced likelihood of hospitalization and death in UPMC patients who received it, especially when administered soon after infection.
A Phase 1 study of Z-endoxifen in patients with solid tumors demonstrated antitumor activity and prolonged stable disease, even in those who had previously responded sub-optimally to tamoxifen. The trial found that 44.4% of patients at certain dose levels achieved partial responses or stable disease.
The TB burden in Europe is decreasing, with a 19% overall decline from 2015-2019. However, drug resistance remains a major concern, and the COVID-19 pandemic may stall or cause setbacks in the fight against TB. Treatment outcomes are suboptimal, with only 77% of patients successfully completing treatment in 2019.
A study analysis found that daily vosoritide treatment for two years improves height gain and body proportionality in children with achondroplasia. This is the first robust evidence of a precision therapy for this condition, which typically affects short stature and bone growth.
Researchers are developing an ocular drug delivery system based on RNA nanotechnology to deliver therapeutics into the eye without requiring eye injections. This method aims to create a reservoir for medications to treat diseases over time, reducing adverse effects and increasing treatment efficiency.
The European Lung Cancer Virtual Congress 2021 will showcase new perspectives in treating small cell lung cancer and mesothelioma, as well as management options for non-small cell lung cancer. More than 200 studies will be presented, with a focus on immunotherapy and lung cancer prevention.
A randomized clinical trial found that participants experiencing homelessness and alcohol use disorder showed significant improvements in reducing drinking and improving health through behavioral harm reduction treatment. The study suggests that traditional abstinence-based treatment may not be effective for this population.
Researchers from NIH's National Institute of Allergy and Infectious Diseases have developed a human cerebral organoid model to screen drugs for potential treatment of Creutzfeldt-Jakob Disease, a fatal neurodegenerative brain disease. The model has shown promise in reducing disease indicators by 10-fold without causing tissue death.
The FDA has qualified the DIBSS-C, a patient-reported outcome measure, to assess symptom-based efficacy endpoints in IBS-C clinical trials. This qualification reflects FDA's commitment to patient-focused drug development and is a major milestone for the IBS Working Group.
New research suggests that unfair police treatment is associated with detrimental outcomes such as depression, suicidal thoughts, drug use, and loss of self-efficacy. The study used a nationally representative sample of over 12,000 participants and found significant disparities in the consequences faced by white and Black people.
A new study aims to explore the cause and therapeutic treatment for left ventricular non-compaction cardiomyopathy (LVNC), also known as a 'spongy heart'. The research, led by University of Houston pharmacologist Mingfu Wu, seeks to determine how heart muscle fails to compact and develop medicines to reduce symptoms.
Fungal infections are rare but deadly, with limited treatment options due to resistance. Developing new antifungals is challenging due to biological similarities between humans and fungi.
Moffitt researchers found that epithelial and mesenchymal subtypes of lung cancer cells respond differently to KRASG12C inhibitor therapy, with varying levels of sensitivity. The study suggests that targeting alternative signaling pathways, such as HER2 and FGFR1, may enhance treatment efficacy.
Researchers identified various molecular pathways and predictive biomarkers of drug resistance in diffuse large B-cell lymphoma. Tailored therapies can improve prognosis for patients with refractory disease, particularly those with specific clinical features.